La Jolla Pharmaceutical to Post FY2022 Earnings of $0.04 Per Share, Jefferies Financial Group Forecasts (NASDAQ:LJPC)

La Jolla Pharmaceutical (NASDAQ:LJPCGet Rating) – Equities research analysts at Jefferies Financial Group cut their FY2022 EPS estimates for shares of La Jolla Pharmaceutical in a note issued to investors on Monday, May 16th. Jefferies Financial Group analyst E. Yang now forecasts that the biopharmaceutical company will earn $0.04 per share for the year, down from their previous estimate of $0.10. Jefferies Financial Group also issued estimates for La Jolla Pharmaceutical’s FY2025 earnings at $0.69 EPS.

La Jolla Pharmaceutical (NASDAQ:LJPCGet Rating) last released its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.16). La Jolla Pharmaceutical had a negative return on equity of 7.34% and a net margin of 10.08%.

A number of other research analysts also recently commented on LJPC. StockNews.com began coverage on La Jolla Pharmaceutical in a report on Thursday, March 31st. They set a “buy” rating on the stock. Zacks Investment Research downgraded La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a report on Thursday.

NASDAQ:LJPC opened at $4.06 on Thursday. The business’s 50 day moving average is $4.17 and its two-hundred day moving average is $4.29. La Jolla Pharmaceutical has a 52 week low of $3.40 and a 52 week high of $5.69. The company has a market cap of $104.02 million, a PE ratio of 27.07 and a beta of 1.94.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. increased its position in La Jolla Pharmaceutical by 0.8% in the 4th quarter. BlackRock Inc. now owns 428,769 shares of the biopharmaceutical company’s stock valued at $1,994,000 after acquiring an additional 3,452 shares during the period. State Street Corp increased its position in La Jolla Pharmaceutical by 4.2% in the 1st quarter. State Street Corp now owns 98,941 shares of the biopharmaceutical company’s stock valued at $422,000 after acquiring an additional 3,962 shares during the period. Northern Trust Corp increased its position in La Jolla Pharmaceutical by 5.3% in the 1st quarter. Northern Trust Corp now owns 80,053 shares of the biopharmaceutical company’s stock valued at $341,000 after acquiring an additional 4,047 shares during the period. Bank of New York Mellon Corp increased its position in La Jolla Pharmaceutical by 4.8% in the 1st quarter. Bank of New York Mellon Corp now owns 127,084 shares of the biopharmaceutical company’s stock valued at $543,000 after acquiring an additional 5,781 shares during the period. Finally, Geode Capital Management LLC increased its position in La Jolla Pharmaceutical by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 283,870 shares of the biopharmaceutical company’s stock valued at $1,319,000 after acquiring an additional 8,454 shares during the period. Hedge funds and other institutional investors own 97.06% of the company’s stock.

La Jolla Pharmaceutical Company Profile (Get Rating)

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.

Further Reading

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.